Effects of Pericapsular Nerve Group Block on Postoperative Recovery for Total Hip Arthroplasty
Launched by UMRANIYE EDUCATION AND RESEARCH HOSPITAL · Dec 13, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a technique called the Pericapsular Nerve Group (PENG) block, which is used to help manage pain for patients undergoing total hip replacement surgery (THA). The researchers believe that giving this nerve block before the surgery, along with spinal anesthesia, can help reduce pain after the operation, decrease the need for strong pain medications like opioids, and allow patients to start moving around sooner.
To be eligible for this trial, participants must be between 40 and 85 years old and scheduled for a THA using a specific surgical approach. However, individuals with certain conditions, such as severe cognitive impairments or other serious health issues, will not be able to participate. If you join the study, you can expect to receive care that focuses on minimizing pain and speeding up recovery, while helping researchers learn more about the benefits of this pain management technique.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • THA performed by posterior approach
- • 40-85 age range
- • ASA 1-3
- Exclusion Criteria:
- • Under 40 years of age, over 85 years of age,
- • ASA 4 and above,
- • Cognitive impairment (Alzheimer's disease, dementia, delirium etc.),
- • Hip fracture,
- • Application site infection,
- • Allergy to local anaesthetic agents,
- • Patients are non-consenting patients.
About Umraniye Education And Research Hospital
Umraniye Education and Research Hospital is a leading healthcare institution dedicated to advancing medical research and education. Located in Istanbul, Turkey, the hospital is renowned for its commitment to providing high-quality patient care while fostering innovation in clinical trials. As a clinical trial sponsor, Umraniye Education and Research Hospital emphasizes ethical standards, rigorous scientific methodology, and collaboration with healthcare professionals and researchers. The institution aims to contribute to the development of new therapies and improve health outcomes through its robust research programs and a multidisciplinary approach to clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Umraniye, Turkey
Patients applied
Trial Officials
zeliha tuncel
Study Director
Ümraniye Training and Education hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported